Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada

Sara Carazo¹, Denis Talbot¹,², Nicole Boulianne³, Marc Brisson¹,²,⁴, Rodica Gilca¹,²,³, Geneviève Deceuninck¹, Nicholas Brousseau¹,²,³, Mélanie Drolet¹, Manale Ouakki³, Chantal Sauvageau¹,²,³, Sapha Barkati⁵,⁶, Élise Fortin³, Alex Carignan⁷, Philippe De Wals²,³, Danuta M. Skowronska⁸, Gaston De Serres¹,²,³

¹Centre de Recherche du CHU de Quebec-Universite Laval, Quebec City, Quebec, Canada
²Social and preventive medicine department, Faculty of medicine, Laval University, Quebec city, Quebec, Canada
³Biological and occupational risks. Institut national de sante publique du Quebec, Quebec City, Quebec, Canada
⁴Department of Infectious Disease Epidemiology, Imperial College London, UK
⁵JD MacLean Centre for Tropical Diseases, McGill University Health Centre, McGill University, Montreal, Canada.
⁶Department of Medicine, Division of Infectious Diseases, McGill University Health Center, McGill University, Montreal, Quebec, Canada.
⁷Department of Microbiology and Infectious Diseases, Sherbrooke University, Sherbrooke, Quebec, Canada.
⁸Communicable Diseases and Immunization Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada.
Corresponding author:
Gaston De Serres MD, PhD
Biological and occupational risks
Institut national de santé publique du Québec
2400, Avenue d'Estimauville
Quebec, Quebec
G1E 7G9, Canada
Phone: +1 418 559 0780
E-mail: gaston.deserres@inspq.qc.ca

Summary: In a test-negative design among healthcare workers in Quebec, Canada, one mRNA vaccine dose reduced the risk of SARS-CoV-2 illness by about three-quarters and associated hospitalization by more than 95%, with substantial single-dose protection persisting at least four months post-vaccination.
ABSTRACT

Introduction: In Canada, first and second doses of mRNA vaccines against SARS-CoV-2 were uniquely spaced 16 weeks apart, but the duration of single-dose protection remains uncertain. We estimated one- and two-dose mRNA vaccine effectiveness (VE) among healthcare workers (HCWs) in Quebec, Canada including protection against varying outcome severity, variants of concern (VOC), and the stability of single-dose protection out to 16 weeks post-vaccination.

Methods: A test-negative design compared vaccination among SARS-CoV-2 test-positive and weekly-matched (10:1), randomly-sampled, test-negative HCWs using linked surveillance and immunization databases. Vaccine status was defined by one dose ≥14 days or two doses ≥7 days before illness onset or specimen collection. Adjusted VE was estimated by conditional logistic regression.

Results: Primary analysis included 5,316 cases and 53,160 controls. Single-dose VE was 70% (95%CI: 68-73) against SARS-CoV-2 infection, 73% (95%CI: 71-75) against COVID-19 illness and 97% (95%CI: 92-99) against associated hospitalization. Two-dose VE was 86% (95%CI: 81-90) and 93% (95%CI: 89-95), respectively, with no associated hospitalizations. VE was higher for non-VOC than VOC (73% Alpha) among single-dose (77%, 95%CI: 73-81 versus 63%, 95%CI: 57-67) but not two-dose recipients (87%, 95%CI: 57-96 versus 94%, 95%CI: 89-96). Across 16 weeks, no decline in single-dose VE was observed with appropriate stratification based upon prioritized vaccination determined by higher versus lower likelihood of direct patient contact.
**Conclusion:** One mRNA vaccine dose provided substantial and sustained protection to HCWs extending at least four months post-vaccination. In circumstances of vaccine shortage, delaying the second dose may be a pertinent public health strategy to consider.

**Key words:** SARS-CoV-2; COVID-19; vaccine effectiveness; healthcare workers; test-negative design
INTRODUCTION

In December 2020, two mRNA vaccines against SARS-CoV-2 were authorized in Canada based upon a schedule of two doses spaced 3 weeks (BNT162b2 (Pfizer-BioNTech)) or 4 weeks (mRNA-1273 (Moderna)) apart[1]. Phase III randomized-controlled trials showed vaccine efficacy that exceeded 90% for both products beginning from 14 days after a single dose but did not inform protection beyond 3-4 weeks post-vaccination[2–5]. Healthcare workers (HCWs) were amongst the first prioritized for COVID-19 vaccination and several observational studies have since reported vaccine effectiveness (VE) after a single dose but most had short follow-up periods, the longest extending 8 weeks post-vaccination[6–10].

In the context of limited vaccine supply, the Quebec Immunization Committee (QIC) recommended that the province of Quebec, Canada defer the second dose of vaccine in order to optimize first-dose coverage and provide protection to as many high-risk individuals as possible against COVID-related hospitalizations and deaths[11]. The QIC did not pre-specify the interval for second-dose administration, relying upon real-time monitoring of single-dose VE and adaptation in the event of waning protection[12]. The vaccination campaign in Quebec began December 14, 2020, and initially targeted long-term care facility (LTCF) residents and HCWs with direct patient contact. On March 3, 2021, the Canadian National Advisory Committee on Immunization and the Quebec Ministry of Health set the interval between doses at 16 weeks based upon expected vaccine supply, ethical considerations and short-term but reassuring VE findings[13,14].

Herein, we compare one- and two-dose mRNA VE against SARS-CoV-2, including varying outcome severity and variants of concern (VOC), among HCWs in Quebec and assess the stability of single-dose protection across 16 weeks post-vaccination.
METHODS

Study design

The study used a test-negative design: HCWs who tested RT-PCR positive for SARS-CoV-2 during the study period were cases; HCWs who tested RT-PCR negative were controls.

The case reference date was defined hierarchically as the date of symptom onset (83.5%) or if not available, then the date of specimen collection (16.5%). The control reference date was defined by specimen collection date. To account for time-varying likelihoods of SARS-CoV-2 exposure and vaccination, a density sampling approach was used with 10 randomly-sampled controls per case matched by week of reference date. A HCW could be sampled several times as a control over the study period (but only once per week) and could subsequently be included as a case. All cases were censored at their reference date.

Population

The study population included all salaried health care workers publicly-funded by the Ministry of Health (e.g. hospital, LTCF, community clinic staff), as well as staff of private facilities under agreement with the Ministry (Supplementary_Figure_S1). Neither physicians who are funded on a fee-for-service basis through a separate source (Medicare) nor HCWs in private-pay settings (e.g. certain clinics, private seniors' residences, pharmacies) are included within this database.

Participants were excluded if: they were a confirmed SARS-CoV-2 case (RT-PCR confirmed or epidemiologically-linked) before January 17, 2021; were missing a unique personal identifying number (PIN) used for data linkage; had an invalid vaccination date (before December 14th); or were <18 or ≥75 years old. HCWs in child and youth
protection centers or those hired temporarily for pandemic work by Ministerial order were also excluded. Finally, AstraZeneca vaccine recipients were excluded from the date of vaccination because their limited number precluded VE estimation.

Data sources

Using the unique PIN, the cohort of all publicly-funded HCWs in the province was linked with: 1) the provincial database of all SARS-CoV-2 infections reported to public health since pandemic start, including associated clinical details collected during case investigation by public health authorities; 2) the administrative hospitalization database and the chronic disease surveillance system, which integrates information on pre-existing medical conditions; 3) the Quebec provincial immunization registry which is a census of all Quebec residents insured under the universal publicly-funded health care system, including whether or not vaccinated, vaccination date(s) and type of vaccine received; 4) the provincial centralized laboratory database, including the dates, results and reason for all RT-PCR tests for SARS-CoV-2 across the province; and 5) VOC PCR screening assay results used to identify signature mutations (69-70 deletion, N501Y, E484K) to genetically characterize and categorize viruses. VOC screening was undertaken on a convenience sample of 10% of SARS-CoV-2 positive specimens in January 2021; on nearly 100% of specimens in February and March; and on about 85% of specimens from April 2021 onwards when the VOC prevalence exceeded 90% [16]. As of June 6, 2021, 89% of identified VOC cases were the Alpha variant (Pango lineage: B.1.1.7) [17].

The study period included HCWs with specimen reference date between January 17 (epidemiological week 3) and June 5 (week 22), 2021 (Figure 1), taking into account the
immunization start-date and a several-week lag for vaccine effect. Data were extracted on June 17th 2021, allowing additional 14-day lag to capture associated hospitalizations.

Vaccination and outcome definitions

Vaccination status was defined in relation to the reference date. In primary analysis, a participant was deemed a single- or two-dose vaccinee if the doses were received ≥14 days or ≥7 days before the reference date (with day of vaccination being day 0), respectively, requiring ≥3 weeks between doses. HCWs who received no vaccine doses at any time on or before the reference date were considered unvaccinated whereas those who received the first dose <14 days or second dose <7 days prior were excluded. RT-PCR confirmed SARS-CoV-2 outcomes of varying severity were explored, including: any infection; symptomatic infection of any severity (specified hereafter as COVID-19); and COVID-19-related hospitalization (occurring within 30 days of illness onset).

VE analysis

Odds ratios (OR) and their 95% confidence intervals (95%CI) among one- and two-dose vaccinees relative to unvaccinated HCWs were estimated by multivariate conditional logistic regression using the matching week as strata and adjusting for potential confounders. VE and 95% CIs were derived as: $1 - OR_{Adjusted} \times 100$.

Adjustment variables included: age group; sex; job category; healthcare setting; region of the healthcare setting (18 in Quebec); and presence of 17 possible comorbidities associated with increased COVID-19 hospitalization risk (known for ~90% of HCWs)[18].

In addition to overall primary analyses by outcome severity, sensitivity analyses included: (a) stratifying by HCW priority group based upon those targeted before
January 31 (week 5) or since February 21 (week 8) reflecting higher and lower frequency of direct patient contact and baseline infection risk, respectively; (b) stratifying by VOC status; (c) restricting to HCWs with data on 17 pre-existing conditions of comorbidity (≥1, ≥2, or by 0, 1, 2, 3, 4, ≥5 conditions); and (d) stratifying by reason for testing (compatible symptoms, outbreak or systematic screening).

**Ethical aspects**

This study was conducted as a surveillance and evaluation protocol with the legal mandate of the National Director of Public Health of Quebec and with the requirement for ethics approval thereby waived under the Public Health Act.

**RESULTS**

**Study population**

Of the 342,138 HCWs in the initial cohort, 333,832 (97.6%) were successfully linked with the immunization registry. As of June 5 (end of week 22), 86.0% of individual HCWs in the cohort had received at least one vaccine dose (88.0% Pfizer-BioNTech, 9.4% Moderna, and 2.6% AstraZeneca vaccine) and 38.9% had received two doses (Figure 1).

We excluded: 8% of HCWs who were confirmed COVID-19 cases before January 17, 2021; 4% who worked in child and youth protection centers; 3% with missing PIN; 1% temporarily hired by Ministerial order; and <1% with an invalid vaccination date.

Among the 284,637 remaining HCWs, 115,288 had no testing during the study period leaving 169,349 HCWs with 548,796 specimens for VE analysis. There were 5,316 cases with 53,160 controls randomly-sampled among negative tests (Supplementary_Figure_S1), of which 10.8% cases and 11.8% controls vaccinated 0-13
days or 0-6 days before the first or second dose, respectively, were excluded from primary analyses.

**Characteristics of cases and controls**

At their reference date, 23.8% of cases and 49.1% of controls had received one dose ≥14 days earlier and 0.9% of cases and 3.9% of controls had received two doses ≥7 days earlier. The percentage of controls vaccinated with at least one dose ≥14 days before the reference date increased with age, from 49.1% in 18-29-year-olds to 61.5% among 60-74-year-olds (Supplementary_Figure_S2). For those who received 2 doses, the median interval between doses was nearly 16 weeks (111 days for cases and 112 days for controls). The median follow-up time for one-dose vaccinees was 56 days and for two-dose vaccinees was 18 days. Among all cases, 80.5% had COVID-19-related symptoms, 1.7% were hospitalized and one unvaccinated HCW died (Table 1). For symptomatic COVID-19 cases, the median and mean interval between symptom onset and testing was 1.0 and 1.3 days, respectively.

Screening PCR for VOC was performed on 2889 (54.4%) positive specimens (91.5% during weeks 8 to 20): 1620 (56.1%) were a VOC and among them 73.0% were the Alpha variant (Table 1), distributed across the study period as displayed in Supplementary_Figure_S3. Demographic and employment characteristics are provided in detail in Table 1.

**Vaccine effectiveness**

**Overall, by outcome severity**

The overall adjusted single-dose mRNA VE was 70.4% (95%CI: 68.2-72.5) against any SARS-CoV-2 infection, 72.9% (95%CI: 70.6-75.0) against COVID-19 and 97.2% (95%CI:
92.3-99.0) against COVID-19-related hospitalization (Table 2). The overall adjusted two-dose mRNA VE was 85.8% (95%CI: 81.0-89.5) and 92.7% (95%CI: 88.5-95.4), respectively, with no associated hospitalizations. No differences were found by vaccine type (Pfizer-BioNTech or Moderna) (Table 2) or age group (Supplementary_Figure_S2).

One-dose VE against COVID-19 was 76-78% between 2- and 7-weeks post-vaccination, declining slightly to about 70% between 9- and 16-weeks post-vaccination (<1% were vaccinated >16 weeks prior) (Figure 2). Follow-up after two doses was too short for corresponding interval analyses.

By HCW priority group

Among HCWs first targeted for vaccination before week 5 (because of highest likelihood of direct patient contact and baseline infection risk), VE during the period 0-13 days after the first dose (when no vaccine effect is expected) was highly negative (-101.6%, 95%CI: -139.9 to -69.5). Conversely, among HCWs first vaccinated after week 8 (at lower baseline infection risk), VE during the period 0-13 days was significantly higher at 43.7% (95%CI: 31.9-53.5). Thereafter, the earlier vs. later targeted HCWs had lower VE overall across the 2-16-week analysis period (52.2%, 95%CI: 47.1-56.9 vs 77.4%, 95%CI: 73.0-81.1), with neither target group showing decline in protection over that extended follow-up period (Supplementary_Table_S1 and Figure 3).

By VOC status

With restriction to cases with screening VOC results, VE against COVID-19 was higher for non-VOC than VOC among single-dose (77.0%, 95%CI: 72.6-80.7 versus 62.5%, 95%CI: 57.4-67.0) but not two-dose recipients (86.5%, 95%CI: 56.8-95.8 versus 93.5%, 95%CI: 88.7-96.3). The Alpha-specific VE did not differ from VE against any VOC
(including those with undetermined lineage) (Table 2) but was consistently lower than for non-VOC across the entire follow-up period (Figure 4). Among 90 hospitalized cases, 63 were analysed for VOC with the only vaccinated case bearing the Alpha variant.

*By comorbidity and testing indication*

Adjustment for the presence of comorbidity did not meaningfully affect VE estimates (data not shown). In analyses stratified by testing indication, one-dose VE was lower for COVID-19 compatible symptoms (62.7%, 95%CI: 58.6-66.4) versus outbreak- (73.0%, 95%CI: 64.7-79.4) or screening-related testing (73.1%, 95%CI: 64.9-79.4). Two-dose estimates were higher for HCWs tested for symptomatic illness but with overlapping 95%CIs (Supplementary_Table_S1).

**DISCUSSION**

In this observational study, we report single-dose mRNA VE of 70% against any SARS-CoV-2 infection and 73% against COVID-19 illness among HCWs in Quebec, Canada. Although VE was higher at 86% and 93%, respectively, after a second dose, VE against COVID-19 hospitalization was comparably high at >95% for both one- and two-dose recipients. Importantly, we provide the longest single-dose vaccination follow-up to date, showing substantial protection maintained for at least 16 weeks after receipt of just one dose of mRNA vaccine. Overall, our findings reinforce the recommendation for second-dose deferral and show that the interval between doses can be extended to at least four months where indicated due to scarce vaccine supply.

Other observational studies from the US, Israel and Europe have reported comparable Pfizer-BioNTech VE among HCWs beginning 14 and 7 days after dose one or two,
respectively, but these involved only short follow-up periods. In two US studies, single-dose VE among HCWs, vaccinated according to the manufacturer’s schedule, was 78% against any infection[6], and 74% against symptomatic infection[7], with two dose VE of 97% and 94%, respectively[6,7]. Similarly, in an Israeli HCW cohort, single-dose VE was 75% against any SARS-CoV-2 infection from 15-28 days post-vaccination[9]. In Italy, single-dose VE between 14-21 days post-vaccination in HCWs was 83% against symptomatic infection and lower at 66% for ≥21 days without specification of the longest duration of follow-up [8]. In the UK, where the second dose was also deferred[19], the SIREN study reported VE against any SARS-CoV-2 infection of 72% from 21 to 69 days post-vaccination in HCWs systematically tested over a maximum of 8 week[10].

In our study, single-dose mRNA VE against hospitalization among HCWs was 97% across a 16-week period. Although evidence elsewhere supports high two-dose protection against hospitalization[20–22], few studies to date have reported single-dose protection and none over such an extended follow up period. In population-based studies, one-dose VE against hospitalizations among mostly older adults was 74% (14-20 days post-vaccination) in Israel, 77% (>14 days post-vaccination) in the US and 91% (14-34 days post-vaccination) in Scotland[21–23].

The Alpha (B.1.1.7) variant was the most prevalent SARS-CoV-2 virus in circulation in Quebec between late March and the end of our study period. The lower single-dose VE of 60% (95%CI: 54% to 66%) we report against symptomatic Alpha infection among HCWs is consistent with the lower single-dose VE of 67% against Alpha infection recently reported for older adults ≥70 years old from the province of British Columbia, Canada also based upon test-negative design[24]. Lower VE against Alpha
may also be explained by greater VOC screening in situations of high-risk exposure such as outbreaks. VE against both VOC and non-VOC during the non-protective period of 0-6 days likely reflects a positive bias in the early period following vaccination, but VE was also lower for Alpha during this period. Our higher two-dose estimate of 93% (95%CI: 87% to 96%) is also consistent with estimates exceeding 90% from Israel[20] and Qatar[25]. Of note, the later predominant contribution by and lower VE against the Alpha variant, whose prevalence among SARS-CoV-2 infections was <30% in mid-March (week 12) but increased to >90% at the end of the study, may have contributed to an apparent but perhaps artefactual decline in overall single-dose protection across the analysis period.

Furthermore, with respect to the question of potential waning of single-dose vaccine protection, we highlight an important methodological issue, critical for other investigators to consider. In particular, we illustrate the impact that confounding by indication can have when averaging VE across sub-groups with different exposure risks and who are sequentially prioritized or targeted for vaccination on that basis. HCWs earliest prioritized for vaccination because of highest baseline infection risk will also contribute most to the longest post-vaccination analysis intervals. In pooled analysis, their systematically higher infection risk and lower VE will lead to an overall, but erroneous, impression of declining single-dose VE generally with time since vaccination. Conversely, with appropriate stratification based upon underlying differential in exposure and infection risk, we show single-dose VE to have been stable across the analysis period including both earlier and later prioritized HCW sub-sets. Properly addressing that methodological bias, we demonstrate no evidence for decrease in single-dose VE across a four-month follow-up period.
This study has limitations, foremost related to its observational design, subject to bias and confounding, and reliance on surveillance data subject to misclassification and missing information. Like others we could not fully adjust for differential exposure risk or fully ascertain the symptom profile notably after specimen testing. Despite easy access to testing, some asymptomatic infections were likely missed. HCWs with undetected infections before the study period could not be excluded leading to bias due to undiagnosed cases among vaccinated (overestimation) or unvaccinated (underestimation) participants[26]. A Ministerial order issued on April 9 requiring unvaccinated HCWs to be systematically tested every 3 days[27] may have increased detection of asymptomatic infections in unvaccinated individuals potentially leading to overestimation of VE against any infection at the end of the follow-up period but without affecting VE against COVID-19 or hospitalization. HCWs are active and relatively young adults and these results may not apply to older adults[28,29]. Even if adjustment for comorbidities did not change VE estimates, HCWs with medical conditions at high risk of severe disease were frequently removed from direct patient care duties during the pandemic and their VE might be lower than the estimates for all HCWs[22]. The Delta variant has more recently risen to prominence, but during the study period comprised <1% of characterized SARS-CoV-2 viruses in Quebec[16], precluding its variant-specific VE estimation. Although the mix of circulating variants and vaccine match may change over time, the over-arching insight we provide is that once established, mRNA VE against a particular strain appears to then be stable across several months. Despite limitations, our study has strengths including its extended post-single-dose follow-up of a large and well-defined cohort and its several sensitivity and stratified analyses to address confounding due to time-dependent variables (vaccination prioritization and exposure risk) and variation in VOC circulation. Whereas
VE estimates from our observational design may not precisely mimic short-term RCT estimates, the stable pattern of persistent single-dose protection we report across several months of follow-up is a unique and informative advantage over prior studies and may be the most meaningful with respect to public health implications for other areas still grappling with vaccine shortage.

In conclusion, one dose of mRNA vaccine reduced the risk of COVID-19 among HCWs by at least three-quarters (preventing three out of four symptomatic infections) and the associated risk of hospitalization by more than 95%, with such single-dose protection extending at least 16 weeks post-vaccination. Our findings of substantial and sustained single-dose VE, including against the Alpha variant, reinforce the option to defer the second dose of mRNA vaccine in circumstances of scarce vaccine supply and where broad single-dose coverage is critically needed.
NOTES

Acknowledgments

We would like to thank Louis Rochette for his work on preparing the healthcare workers’ dataset.

Funding

This work was supported by the Ministère de la santé et des services sociaux du Québec.

Potential conflicts of interest

DT is supported by a “Chercheur-boursier” junior-1 career award from the Fonds de recherche du Québec – Santé. GDS received a grant from Pfizer for anti-meningococcal immunogenicity study not related to this study and reports funding by the Ministry of Health of Quebec to the Public Health Institute to develop the research project (paid to institution). AC reports grants or contracts with Pfizer as PI for the CLOVER study. DMS reports grants or contracts with Public Health Agency of Canada, Michael Smith Foundation for Health Research, and Canadian Institutes of Health Research unrelated to the current work, paid to institution. PDW reports that the study was funded by the Quebec Ministry of Health and Social Services directed to and administered by the Quebec National Public Health Institute; ‘ministère de la Santé et des Services sociaux du Québec’ ‘Institut national de santé publique du Québec’. SC reports that the study was funded by the Ministry of Health and payments were made through the Institute of Public Health of Quebec.
REFERENCES

1. National Advisory Committee on Immunization (NACI). Recommendations on the use of COVID-19 Vaccines. Ottawa: NACI. Available at: https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines/recommendations-use-covid-19-vaccines-en.pdf. Accessed 10 June 2021.

2. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med, 2020; 383:2603–2615.

3. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med, 2021; 384:403–416.

4. Skowronski DM, De Serres G. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med, 2021; 384:1576–1577.

5. Moderna COVID-19 Vaccine. FDA Briefing Document. Vaccines and Related Biological Products Advisory Committee Meeting. December 17, 2020. 2020. Available at: https://www.fda.gov/media/144434/download. Accessed 10 June 2021.

6. Pilishvili T, Fleming-Dutra KE, Farrar JL, et al. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021. MMWR Morb Mortal Wkly Rep, 2021; 70:753–758.
7. Swift MD, Breeher LE, Tande AJ, et al. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel. Clinical Infectious Diseases, 2021; ciab361.

8. Fabiani M, Ramigni M, Gobbetto V, Mateo-Urdiales A, Pezzotti P, Piovesan C. Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021. Eurosurveillance, 2021; 26.

9. Amit S, Beni SA, Biber A, Grinberg A, Leshem E, Regev-Yochay G. Postvaccination COVID-19 among Healthcare Workers, Israel. Emerg Infect Dis, 2021; 27:1220–1222.

10. Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. The Lancet, 2021; 397:1725–1735.

11. Comité sur l’immunization du Québec. Stratégie de vaccination contre la COVID-19 : report de la 2e dose en contexte de pénurie. Available at: https://www.inspq.qc.ca/publications/3098-strategie-vaccination-2e-dose-covid. Accessed 10 June 2021.

12. Comité sur l’immunization du Québec. Demande complémentaire pour l’avis Stratégie de vaccination contre la COVID-19 : report de la 2e dose en contexte de pénurie. Available at: https://www.inspq.qc.ca/publications/3103-vaccination-2e-dose-contexte-penurie-covid19. Accessed 10 June 2021.
13. National Advisory Committee on Immunization (NACI). NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. Available at: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html. Accessed 10 June 2021.

14. Ministère de la Santé et des Services Sociaux. Pandémie de la COVID-19 - Un intervalle de 16 semaines entre les deux doses de vaccin. Available at: https://www.msss.gouv.qc.ca/ministere/salle-de-presse/communique-2676/. Accessed 10 June 2021.

15. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. Third edition. Lippincott Williams & Wilkins, 2008.

16. Institut national de santé publique du Québec. Données sur les variants du SRAS-CoV-2 au Québec. Available at: https://www.inspq.qc.ca/covid-19/donnees/variants. Accessed 18 August 2021.

17. National Collaborating Centre for Infectious Diseases. Updates on COVID-19 Variants of Concern. Available at: https://nccid.ca/covid-19-variants/. Accessed 10 June 2021.

18. Simard M, de Montigny C, Sonia J, Fortin E. Impact of comorbidities on the risk of death and hospitalization among confirmed cases of COVID-19 during the first months of the pandemic in Québec. Institut national de santé publique du Québec, 2020. Available at: 
19. Iacobucci G, Mahase E. Covid-19 vaccination: What’s the evidence for extending the dosing interval? BMJ, 2021; :n18.

20. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet, 2021; 397:1819–1829.

21. Vahidy FS, Pischel L, Tano ME, et al. Real World Effectiveness of COVID-19 mRNA Vaccines against Hospitalizations and Deaths in the United States. MedRxiv 21255873 [Preprint]. 2021. Available at: http://medrxiv.org/lookup/doi/10.1101/2021.04.21.21255873. Accessed 16 June 2021.

22. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med, 2021; 384:1412–1423.

23. Vasileiou E, Simpson CR, Robertson C, et al. Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. SSRN Journal, 2021.

24. Skowronski DM, Setayeshgar S, Zou M, et al. Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including Alpha and Gamma variants: a test-negative design in adults 70 years and older in British Columbia, Canada. Clinical Infectious Diseases, 2021; :ciab616.
25. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med, 2021; 385:187–189.

26. Krammer F, Srivastava K, Alshammary H, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med, 2021; 384:1372–1374.

27. Ministère de la Santé et des Services Sociaux du Québec. Arrêté numéro 2021-024 du ministre de la Santé et des Services sociaux en date du 9 avril 2021. Available at: https://cdn-contenu.quebec.ca/cdn-contenu/adm/min/sante-services-sociaux/publications-adm/lois-reglements/AM_2021-024.pdf?1618075211. Accessed 10 June 2021.

28. Lopez Bernal J, Andrews N, Gower C, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. MedRxiv 21252652 [Preprint]. 2021. Available at: http://medrxiv.org/lookup/doi/10.1101/2021.03.01.21252652. Accessed 10 July 2021.

29. Hyams C, Marlow R, Maseko Z, et al. Assessing the Effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 Vaccination in Prevention of Hospitalisations in Elderly and Frail Adults: A Single Centre Test Negative Case-Control Study. SSRN Journal, 2021;
Tables

Table 1. Vaccination status, demographic and employment characteristics of cases and controls

|                           | CASES            | CONTROLS        |
|---------------------------|------------------|-----------------|
|                           | Any SARS-CoV-2   | COVID-19        | Hospitalizations |
|                           | infections       |                 |                 |
| N=5316                    | N=4277           | N=92            | N=53160         |
| N                         | %                | N               | %               | N               | %               |
| Vaccination status (days before illness onset/testing) |                  |                 |                 |
| One-dose vaccinees (≥14 days) | 1266, 23.8%     | 970, 22.7%     | 4, 4.4%         | 26118, 49.1%   |
| **PFIZER-BioNTech vaccine** | 1202, 22.6%     | 924, 21.6%     | 4, 4.4%         | 24589, 46.3%   |
| **MODERNA vaccine**       | 64, 1.2%         | 46, 1.1%       | 0, 0.0%         | 1529, 2.9%     |
| Two-dose vaccinees (≥7 days) | 50, 0.9%        | 20, 0.5%       | 0, 0.0%         | 2081, 3.9%     |
| **PFIZER-BioNTech vaccine** | 48, 0.9%        | 20, 0.5%       | 0, 0.0%         | 1954, 3.7%     |
| **MODERNA vaccine**       | 2, 0.0%          | 0, 0.0%        | 0, 0.0%         | 126, 0.2%      |
| Vaccinated with at least 1 dose (≥14 days) a | 1373, 25.8%     | 1029, 24.1%    | 4, 4.4%         | 29201, 54.9%   |
| Unvaccinated              | 3424, 64.4%     | 2813, 65.8%    | 86b, 18663      | 35.1           |
| Delay between doses in days (median and IQR) | 111, 106–112 | 112, 109–NA | NA, 112         | 107–112        |
| Reasons for testing       |                  |                 |                 |
| Symptoms compatible with COVID-19 | 2751, 51.8%   | 2619, 61.2%    | 44, 47.8%       | 8094, 15.2%    |
| Testing in the presence of an outbreak | 629, 11.8%     | 407, 9.5%      | 6, 6.5%         | 12517, 23.6%   |
| Systematic screening (asymptomatic) | 653 | 12.3 | 373 | 8.7 | 7 | 7.6 | 23940 | 45.0 |
|---|---|---|---|---|---|---|---|---|
| Other reason or unknown | 1283 | 24.1 | 878 | 20.5 | 35 | 38.0 | 8609 | 16.2 |

**Variants of concern (among 2889 positive specimens)**

| Variants of concern | 1620 | 56.1 | 1368 | 58.1 | 43 | 67.2 | NA |
|---|---|---|---|---|---|---|---|
| Alpha variant (lineage B.1.1.7) | 1182 | 40.9 | 1003 | 42.6 | 31 | 48.4 | NA |
| VOC not detected | 944 | 32.7 | 784 | 33.3 | 15 | 23.4 | NA |
| Uninterpretable result | 325 | 11.2 | 203 | 8.6 | 6 | 9.4 | NA |

**Demographic, clinical and employment characteristics**

| Age (median and IQR) | 39 | 30-49 | 39 | 30-49 | 48.5 | 38-56 | 41 | 31-51 |
|---|---|---|---|---|---|---|---|---|
| 18-29 years | 1295 | 24.4 | 1049 | 24.5 | 9 | 9.8 | 10826 | 20.4 |
| 30-39 years | 1403 | 26.4 | 1157 | 27.1 | 17 | 18.5 | 13642 | 25.7 |
| 40-49 years | 1343 | 25.3 | 1067 | 25.0 | 24 | 26.1 | 13569 | 25.5 |
| 50-59 years | 1049 | 19.7 | 828 | 19.4 | 31 | 33.7 | 11957 | 22.5 |
| 60-74 years | 226 | 4.3 | 176 | 4.1 | 11 | 12.0 | 3166 | 6.0 |
| Sex, female | 4233 | 79.6 | 3459 | 80.9 | 69 | 75.0 | 44280 | 83.3 |

**Comorbidity (n=53075; 90.8%)**

| At least one medical condition | 1617 | 30.8 | 1302 | 30.6 | 49 | 53.3 | 15963 | 33.1 |
|---|---|---|---|---|---|---|---|---|
| At least two medical conditions | 502 | 9.5 | 415 | 9.8 | 21 | 22.8 | 4845 | 10.1 |

**Job category**

| Nurse | 975 | 18.3 | 801 | 18.7 | 16 | 17.4 | 12519 | 23.6 |
|---|---|---|---|---|---|---|---|---|
| Nursing assistant | 474 | 8.9 | 372 | 8.7 | 12 | 13.0 | 4516 | 8.5 |
| Healthcare support worker | 1108 | 20.8 | 817 | 19.1 | 29 | 1.1 | 12357 | 23.2 |
| Other health assisting occupations | 662 | 12.5 | 503 | 11.8 | 10 | 31.5 | 5430 | 10.2 |
a Including those vaccinated with 2 doses less than 7 days before the reference date

b 2 hospitalized cases were vaccinated 0-13 days before illness onset

c 17 medical conditions considered: hypertension, cardiovascular disease, neurological disorder, anemia, respiratory disease, diabetes, hypothyroidism, fluid and electrolyte disorder, cancer, kidney disease, obesity, psychosis, liver disease, immune disease, coagulopathy and paralysis

Abbreviations: IQR=Interquartile range; NA=not applicable; VOC=Variant of concern
Table 2. Overall vaccine effectiveness by outcome severity (SARS-CoV-2 infection, COVID-19 and COVID-19-related hospitalization) and by variant of concern status

| Model adjusted (stratified) for the matching week | Model fully adjusted<sup>a</sup> |
|-----------------------------------------------|---------------------------------|
| Cases (%)                  | Controls (%)                  | VE   | 95% CI | VE   | 95% CI |
|----------------------------|--------------------------------|------|--------|------|--------|
| **Overall, by outcome severity**                   |                                |      |        |      |        |
| **1. VE against any SARS-CoV-2 infection**        |                                |      |        |      |        |
| One-dose vaccinees (≥14 days)                      | 1266 (26.7)        | 26118 (55.7) | 74.7% | 72.9 – 76.4 | 70.4% | 68.2 – 72.5 |
| *PFIZER-BioNTech vaccine*                          | 1202 (25.7)        | 24589 (54.4) | 74.5% | 72.6 – 76.2 | 70.3% | 68.1 – 72.4 |
| *MODERNA vaccine*                                  | 64 (1.8)           | 1529 (7.5)  | 78.0% | 71.6 – 82.9 | 68.7% | 59.5 – 75.9 |
| Two-doses vaccinees (≥7 days)                      | 50 (1.0)           | 2081 (4.4)  | 89.3% | 85.6 – 92.0 | 85.8% | 81.0 – 89.5 |
| *PFIZER-BioNTech vaccine*                          | 48 (1.0)           | 1954 (4.3)  | 89.0% | 85.2 – 91.8 | 85.5% | 80.4 – 89.3 |
| *MODERNA vaccine*                                  | 2 (0.1)            | 126 (0.6)   | 90.4% | 61.2 – 97.6 | 84.1% | 34.9 – 96.1 |
| Unvaccinated                                       | 3424 (72.2)        | 18663 (39.8) |      |         |      |        |
| **2. VE against COVID-19**                         |                                |      |        |      |        |
| One-dose vaccinees (≥14 days)                      | 970 (25.5)         | 26118 (55.7) | 76.7% | 74.9 – 78.5 | 72.9% | 70.6 – 75.0 |
| *PFIZER-BioNTech vaccine*                          | 924 (24.6)         | 24589 (54.4) | 76.4% | 74.5 – 78.2 | 72.8% | 70.5 – 74.9 |
| *MODERNA vaccine*                                  | 46 (1.6)           | 1529 (7.5)  | 80.9% | 74.3 – 85.8 | 80.9% | 74.3 – 85.8 |
| Two-doses vaccinees (≥7 days)                      | 20 (0.5)           | 2081 (4.4)  | 94.4% | 91.3 – 96.5 | 92.7% | 88.5 – 95.4 |
|                      | PFIZER-BioNTech vaccine | MODERNA vaccine | Unvaccinated |
|----------------------|-------------------------|-----------------|--------------|
|                      | 20 (0.5)                | 0 (0)           | 2813 (74.0)  |
|                      | 1954 (4.3)              | 126 (0.6)       |              |
| VE against COVID-19-related hospitalisation |                        |                 |              |
| One-dose vaccinees (≥14 days) | 4 (4.4) | 26118 | 97.1% | 92.0 – 98.9 | 97.2% | 92.3 – 99.0 |
| Two-doses vaccinees (≥7 days) | 0 (0.0) | 2081 (4.4) | 100% | NE | NE | NE |
| Unvaccinated | 86 (96.6) | 18663 | NE | NE | NE | NE |

**By VOC status**

1. Any VOC detected

|                      | PFIZER-BioNTech vaccine | MODERNA vaccine | Unvaccinated |
|----------------------|-------------------------|-----------------|--------------|
|                      | 454 (36.3)              | 13 (1.0)        | 784 (62.7)   |
|                      | (55.7)                  | (1.4)           | (39.8)       |
|                      | 67.4%                   | 94.8%           | 62.5%        |
|                      | 63.2 – 71.1             | 90.8 – 97.0     | 57.4 – 67.0  |
|                      | 62.5%                   | 93.5%           | 88.7 – 96.3  |

2. Alpha variant

|                      | PFIZER-BioNTech vaccine | MODERNA vaccine | Unvaccinated |
|----------------------|-------------------------|-----------------|--------------|
|                      | 337 (37.4)              | 13 (1.4)        | 551 (61.2)   |
|                      | (55.7)                  | (1.4)           | (39.8)       |
|                      | 63.9%                   | 94.0%           | 53.6 – 65.5  |
|                      | 58.5 – 68.7             | 89.5 – 96.6     | 87.1 – 95.8  |
|                      | 60.0%                   | 92.6%           |              |

3. VOC not detected

|                      | PFIZER-BioNTech vaccine | MODERNA vaccine | Unvaccinated |
|----------------------|-------------------------|-----------------|--------------|
|                      | 187 (25.2)              | 2081 (4.4)      | 865 (65.8)   |
|                      | (55.7)                  | (4.4)           | (39.8)       |
|                      | 81.4%                   | 90.2%           | 56.8 – 95.8  |
|                      | 77.9 – 84.3             | 68.6 – 97.0     |              |
|                      | 77.0%                   | 86.5%           |              |
|                      | 72.6 – 80.7             |                 |              |
| Unvaccinated | 18663 |
|--------------|-------|
| 552 (74.4)   | (39.8) |

*Conditional logistic regression model adjusted for: age group (18-29, 30-39, 40-49, 50-59, 60-74 years); sex, job category (nurse, nursing assistant, personal healthcare support worker, other technical and health assisting occupations, administrative and management staff, healthcare technician, social workers, others); health care setting, health region and matching week.

Abbreviations: CI=confidence interval; NE=not estimable; VE=vaccine effectiveness; VOC=variant of concern*
**Figure legends**

**Figure 1.** Vaccination coverage in the cohort of healthcare workers and total number of reported COVID-19 cases in the population per week, Quebec, Canada.

**Figure 2.** Vaccine effectiveness against COVID-19 by interval since vaccination

Abbreviations: VE=Vaccine effectiveness; CI=Confidence Interval

**Figure 3.** Vaccine effectiveness against COVID-19 in healthcare workers vaccinated before January 31st 2021 (highest contacts with patients) and those vaccinated after February 20th 2021 (fewer contacts with patients) by interval since vaccination

Abbreviations: VE=Vaccine effectiveness; CI=Confidence Interval

**Figure 4.** Vaccine effectiveness against COVID-19 by variant of concern (VOC) status (non-VOC or Alpha variant) by interval since vaccination

Abbreviations: VE=Vaccine effectiveness; VOC=Variant of concern; CI=Confidence Interval
Figure 1

Study period (weeks 3 to 22)

Vaccine coverage vs. Number of declared cases in the population over time for different vaccine types and weeks.
Figure 2

![Graph showing vaccine effectiveness against COVID-19 over different age groups and time intervals after vaccination.](image-url)
Figure 3

![Graph showing vaccine effectiveness over time and across different age groups. The graph includes data for vaccinated individuals before and after February 21, with intervals post-dose one and two. The x-axis represents days since vaccination, while the y-axis shows vaccine effectiveness percentage.]
Figure 4

![Figure 4](image-url)